Home Compare GSK.L vs ROG.SW
Stock Comparison · Industry comparison · Drug Manufacturers - General

GSK vs Roche Holding: Which Stock Looks Stronger in 2026?

The structural profiles are close, with GSK carrying a narrow edge on profitability. Roche still has the edge on profitability, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The page question resolves through profitability, where Roche Holding AG holds the stronger read even though the broader score still favours GSK plc.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. GSK.L and ROG.SW share the same industry classification.

For a similarity-based comparison, see how GSK and Roche each position within their functional peer groups in AssetNext.

Peer-Relative Score
GSK.L
GSK plc
65
Peer-Score
Signal qualityHigh
vs
ROG.SW
Roche Holding AG
63
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: GSK.L vs ROG.SW Profitability 46 75 Stability 69 51 Valuation 80 64 Growth 71 55 GSK.L ROG.SW
Gap Ranking
#1 Profitability +29
#2 Stability +18
#3 Growth +16
#4 Valuation +16
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GSK.L and ROG.SW Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GSK.LROG.SW Relative valuation Structural strength

The structural gap is limited here, but current pricing still leans against Roche Holding AG.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Both rank well on profitability, but Roche Holding AG still holds a clear edge.
Stability
On stability, the edge still sits with GSK plc, even though both profiles look solid.
Profitability — Dominant Gap
GSK.L
46
ROG.SW
75
Gap+29in favour of ROG.SW

Return on equity adds support too, with a 6-point advantage.

What else supports the lead

Stability also supports the lead, so the result is broader than one isolated gap.

What this means for the comparison

The lead is built on both profitability and stability — though profitability still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the GSK.L vs ROG.SW comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how GSK.L and ROG.SW each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.